+

WO2006000158A8 - Utilisation de laetispicine pour la fabrication d'une composition pharmaceutique - Google Patents

Utilisation de laetispicine pour la fabrication d'une composition pharmaceutique

Info

Publication number
WO2006000158A8
WO2006000158A8 PCT/CN2005/000912 CN2005000912W WO2006000158A8 WO 2006000158 A8 WO2006000158 A8 WO 2006000158A8 CN 2005000912 W CN2005000912 W CN 2005000912W WO 2006000158 A8 WO2006000158 A8 WO 2006000158A8
Authority
WO
WIPO (PCT)
Prior art keywords
laetispicine
reuptake
pharmaceutical composition
monoamine neurotransmitter
manufacture
Prior art date
Application number
PCT/CN2005/000912
Other languages
English (en)
Chinese (zh)
Other versions
WO2006000158A1 (fr
Inventor
Sheng-Li Pan
Fu-Gang Qian
Jun Wang
Feng-Yan Sun
Jing Xie
Yi-Ci Shao
Original Assignee
Univ Fudan
Sheng-Li Pan
Fu-Gang Qian
Jun Wang
Feng-Yan Sun
Jing Xie
Yi-Ci Shao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Fudan, Sheng-Li Pan, Fu-Gang Qian, Jun Wang, Feng-Yan Sun, Jing Xie, Yi-Ci Shao filed Critical Univ Fudan
Publication of WO2006000158A1 publication Critical patent/WO2006000158A1/fr
Publication of WO2006000158A8 publication Critical patent/WO2006000158A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne l'utilisation de laetispicineur la fabrication d'une composition pharmaceutique destin inhiber la recapture du neurotransmetteur monoamine du système nrvu central, pour le traitement des maladies associées induitesparlarecapture du neurotransmetteur monoamine du système nerveu cenral
PCT/CN2005/000912 2004-06-25 2005-06-24 Utilisation de laetispicine pour la fabrication d'une composition pharmaceutique WO2006000158A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB2004100254930A CN1332656C (zh) 2004-06-25 2004-06-25 化合物大叶蒟素在制备药物组合物中的应用
CN200410025493.0 2004-06-25

Publications (2)

Publication Number Publication Date
WO2006000158A1 WO2006000158A1 (fr) 2006-01-05
WO2006000158A8 true WO2006000158A8 (fr) 2006-02-09

Family

ID=34663697

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2005/000912 WO2006000158A1 (fr) 2004-06-25 2005-06-24 Utilisation de laetispicine pour la fabrication d'une composition pharmaceutique

Country Status (2)

Country Link
CN (1) CN1332656C (fr)
WO (1) WO2006000158A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101798297B (zh) * 2009-02-11 2013-02-27 中国科学院上海药物研究所 大叶蒟素的化学合成方法
CN102240281B (zh) * 2010-05-12 2014-05-14 天士力制药集团股份有限公司 5′-甲氧基-3′，4′-次甲二氧基桂皮酸异丁基酰胺在制备抗抑郁药物中的应用
CN102775394B (zh) * 2011-05-12 2016-03-09 天士力制药集团股份有限公司 一种酰胺类化合物及其制备方法和应用
CN104513172B (zh) * 2013-09-30 2018-02-02 天士力医药集团股份有限公司 含有三氟甲基的酰胺生物碱、制备方法及其药物用途
CN104940821A (zh) * 2015-06-28 2015-09-30 李先强 一种治疗余光恐惧症的中药

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1389462A (zh) * 2002-07-12 2003-01-08 复旦大学 大叶蒟素及其同系物，和在制备药物组合物中的应用

Also Published As

Publication number Publication date
WO2006000158A1 (fr) 2006-01-05
CN1593399A (zh) 2005-03-16
CN1332656C (zh) 2007-08-22

Similar Documents

Publication Publication Date Title
WO2007081542A3 (fr) Inhibiteurs de recaptage de monoamine a base de tetralone
TW200732296A (en) Novel compounds
TW200740799A (en) Alpha2C adrenoreceptor agonists
TW200745003A (en) Novel compounds
MX337933B (es) Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal.
WO2006124748A3 (fr) Composes polycycliques et procedes pour les utiliser
WO2010078421A8 (fr) Composés de 5,6-dihydro-6-phénylbenzo[f]isoquinoléine-2-amines substituées
SG179120A1 (en) Novel compounds
WO2008137923A3 (fr) Droxidopa et composition pharmaceutique de celle-ci pour le traitement des troubles de l'humeur, des troubles du sommeil, ou de troubles déficitaires de l'attention
WO2007061939A3 (fr) Dérivés de métabolites de l'inhibiteur de hdac fk228
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
WO2007022225A3 (fr) Composes nitres cycliques, compositions pharmaceutiques contenant ces composes et leurs applications
MX2010003117A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
WO2007081857A3 (fr) Cycloalkylamines inhibiteurs du recaptage des monoamines
WO2007143607A3 (fr) Procédé de traitement de la vaginite atrophique
SG162747A1 (en) Erythropoietin receptor peptide formulations and uses
WO2008144061A3 (fr) Nouvelles compositions comprenant un inhibiteur de phosphodiestérase-5 et leur utilisation dans des procédés de traitement
WO2010078369A3 (fr) Inhibiteurs de pyrimidinediamine kinase
MX368459B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
HK1105197A1 (en) Pyrimido-benzimidazole derivatives and the use thereof in the form of agonists or antagonists of melanocortin receptors
WO2007035872A3 (fr) Composés apparentés au fdt et leurs analogues
WO2006091836A8 (fr) Preparations de tartrate de ladostigil

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: PUBLISHED FIGURE REPLACED BY CORRECT FIGURE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载